NPI 1306012026: Open Payments
NPI 1306012026. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$301 in 12 payments from 10 companies in 2025. Trend: 2023 $319 · 2024 $158 · 2025 $301
Food & beverage: $201Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 1 | $100 |
| Sage Therapeutics, LLC | 2 | $36 |
| Exeltis, USA Inc. | 2 | $31 |
| Organon LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| PFIZER INC. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Exact Sciences Corporation | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $15 |
Products named: ZURZUVAE, SLYND, NEXPLANON, ZEPBOUND, ABRYSVO, Mirena, The Cologuard Plus Collection Kit, Qelbree.
